Kristine Ashcraft, Chief Executive Officer

Ashcraft joined Genelex in 2000, and has served in several roles, including Director of Sales and Marketing and Chief Operating Officer, prior to her promotion to CEO in 2015.

Ashcraft defines the company’s overall strategy, vision, and place in the pharmacogenetics industry. She is responsible for business development, product design, market share and internal systems, in addition to being the primary liaison for governmental agencies, clients, and partners. Under her leadership, Genelex sales have more than doubled multiple years in a row.

Prior to joining Genelex, Kristine worked in sales management at an insurance provider and was responsible for establishing training and protocols that helped spur over 2000% growth in three years. Ashcraft has also served in management roles in the non-profit sector.

She obtained her MBA in Entrepreneurship, graduating magna cum laude from the Franklin W. Olin Graduate School of Business at Babson College, and BS in Molecular Biology from the University of New Haven.


Howard C. Coleman, Chairman

Coleman co-founded Genelex in 1987 and currently serves as Chairman of the Board.

As the former CEO, Coleman was the leading visionary behind the establishment of Genelex as a world leader in pharmacogenetic testing and medication management analytics software.

In addition to working at Genelex, Coleman is a Principal at Biotech Trends, LLC. He has also served as a member of the Washington State Board of Health Genetics Task Force and as faculty at the Institute for Science Training and Research.  He has served as expert testimony in multiple legal cases, has written multiple publications, and is an inventor on multiple patents.

Coleman has a BS in Clinical Science and a BA in psychology and studied at the University of Washington and Fred Hutchinson Cancer Research Center.


Tia Aulinskas, PhD, Chief Scientific Officer, Lab Director and Board Member

Dr. Aulinskas co-founded Genelex in 1987 and currently serves as Chief Scientific Officer, Laboratory Director, and Board Secretary. Aulinskas brings more than 30 years of experience in the field of DNA testing.

Dr. Aulinskas leads and manages laboratory science and business operations, financial administration, and product development. Technologies implemented include genotyping, gene sequencing, probe manufacture, contract research services, and FDA product release testing. She has secured all laboratory accreditation and licensing including CAP, CLIA, NYDOH, AABB, ASCLD/LAB, and maintained regulatory compliance with a variety of agencies. She has directed laboratory services for multiple national, international, state and federal justice system agencies, biotechnology companies, contract clients, hospitals and individuals.

Prior to co-founding Genelex, Dr. Aulinskas served as a senior research fellow in the Pathology Department and Division of Metabolism, Endocrinology and Nutrition at the University of Washington.

Dr. Aulinskas holds a doctorate and a BS, cum laude, in medical biochemistry from the University of Cape Town, South Africa and a MS in medical biochemistry from the University of Stellenbosch.


Bob Patterson, M.D., Chief Information Officer

Dr. Patterson joined Genelex in 2007 as Chief Information Officer. Dr. Patterson has been authoring software to improve patient care since 1983. Dr. Patterson has more than 40 years of experience as a psychiatrist and is on the attending staff of McLean Hospital and has an appointment at Harvard Medical School.

Dr. Patterson developed GeneMedRX, which was the first iteration of the YouScript analytics software. Patterson designs, programs and maintains the clinical algorithms that power YouScript.

Prior to working with Genelex, Dr. Patterson was president of Mental Health Connections, Inc. Since 1996, Bob has sat on the subcommittee for Informatics and Decision Support at Harvard’s Institute of Cybermedicine. He has written multiple scientific publications and is an inventor on multiple patents.

Dr. Patterson received his MD from the George Washington University Medical School. He is on the attending staff of McLean Hospital and holds an appointment at Harvard Medical School.


Gregory Alderson, CPA, Executive Vice President and Board Member

Alderson joined Genelex in 2012 as Executive Vice President and has been a member of the Board of Directors since 1987. Alderson has extensive biotechnology and software experience with startups and Fortune 500 companies.

Alderson’s role is to apply entrepreneurial and executive level advisory skills helping guide and foster the Company’s growth.

Prior to Genelex, he served as chairman and CEO of Invizeon Corporation, a provider of advanced communications solutions. Alderson has also served in finance, operations and marketing executive management roles at BioXcelerator, Microsoft, Raima, General Information, Advanced Products & Technologies, Bristol Myers Squibb, and Genetic Systems. Alderson is a former CPA earned while at the Big 4 accounting firm, Deloitte Haskins & Sells (known now as Deloitte).

Alderson earned his MBA from the University of Oregon. He also holds BS degrees in Microbiology and Immunology and in Food Science, both from the University of Washington.


John Nelson, M.D., Medical Director

Nelson joined Genelex in 2013 as Medical Director. Dr. Nelson, MD, MPH is a board-certified OB/GYN with over 30 years of clinical practice and was president of the American Medical Association from 2004-2005.

Dr. Nelson serves as the Genelex’s liaison to physicians, specialists, and organizations, helping to them to understand the clinical benefits of using pharmacogenetics to predict adverse drug event risk and develop protocols for incorporating gene-based prescribing into their workflow.

Dr. Nelson has been in active clinical practice of obstetrics and gynecology since 1975 and currently sees patients at the Health Clinics of Utah. He was a charter member of the Prospective Payment Assessment Commission (now MedPAC) and has recently served on the Advisory Committee to the Director of the National Institutes of Health (NIH). He is currently the Chief Medical Officer at Leavitt Partners in Salt Lake City, Utah.

Dr. Nelson graduated from the University of Utah School of Medicine.